PIAS family in cancer: from basic mechanisms to clinical applications.

PIAS SUMOylation activators of transcription factor (STAT) signal transducers transcriptional factor

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 25 01 2024
accepted: 06 03 2024
medline: 9 4 2024
pubmed: 9 4 2024
entrez: 9 4 2024
Statut: epublish

Résumé

Protein inhibitors of activated STATs (PIAS) are proteins for cytokine signaling that activate activator-mediated gene transcription. These proteins, as versatile cellular regulators, have been described as regulators of approximately 60 proteins. Dysregulation of PIAS is associated with inappropriate gene expression that promotes oncogenic signaling in multiple cancers. Multiple lines of evidence have revealed that PIAS family members show modulated expressions in cancer cells. Most frequently reported PIAS family members in cancer development are PIAS1 and PIAS3. SUMOylation as post-translational modifier regulates several cellular machineries. PIAS proteins as SUMO E3 ligase factor promotes SUMOylation of transcription factors tangled cancer cells for survival, proliferation, and differentiation. Attenuated PIAS-mediated SUMOylation mechanism is involved in tumorigenesis. This review article provides the PIAS/SUMO role in the modulation of transcriptional factor control, provides brief update on their antagonistic function in different cancer types with particular focus on PIAS proteins as a bonafide therapeutic target to inhibit STAT pathway in cancers, and summarizes natural activators that may have the ability to cure cancer.

Identifiants

pubmed: 38590645
doi: 10.3389/fonc.2024.1376633
pmc: PMC10999569
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1376633

Informations de copyright

Copyright © 2024 Li, Rasul, Sharif and Hassan.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Xiaomeng Li (X)

KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong, China.

Azhar Rasul (A)

Department of Zoology, Government College University Faisalabad, Faisalabad, Pakistan.

Farzana Sharif (F)

Department of Zoology, Government College University Faisalabad, Faisalabad, Pakistan.

Mudassir Hassan (M)

Department of Zoology, Government College University Faisalabad, Faisalabad, Pakistan.

Classifications MeSH